Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
To report the short term anatomic and visual acuity response after intravitreal injection of
bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil) in patients with choroidal
neovascularization secondary to age-related macular degeneration.